Pharmacological treatment of sleep apnea: Current situation and future strategies

Sleep Medicine Reviews

Volumn 12, Issue 1, 2008, Pages 33-47

  Hedner, Jan ^a   Grote, Ludger ^a   Zou, Ding ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetazolamide; Acetylcholine; Central sleep apnea; Hormones; Hypertension; Obesity; Obstructive sleep apnea; Pharmacological treatment; Serotonin; Theophylline

Indexed keywords

4 AMINOBUTYRIC ACID; ACETAZOLAMIDE; ACETYLCHOLINE; AMINOPHYLLINE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUOXETINE; GLUTAMIC ACID; MIRTAZAPINE; MONOAMINE; NICOTINE; PAROXETINE; PHYSOSTIGMINE; PLACEBO; PROTRIPTYLINE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

BEDTIME DOSAGE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DAYTIME SOMNOLENCE; DISEASE SEVERITY; ENDOCRINE DISEASE; HUMAN; HYPERTENSION; METABOLIC DISORDER; NONHUMAN; OBESITY; PATIENT SELECTION; PHENOTYPE; REVIEW; SLEEP APNEA SYNDROME;

ANIMALS; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CONTINUOUS POSITIVE AIRWAY PRESSURE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FORECASTING; HUMANS; PATIENT COMPLIANCE; PATIENT SELECTION; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 38049022464     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2007.06.002     Document Type: Review

References (128)

1. Zozula R., and Rosen R. Compliance with continuous positive airway pressure therapy: assessing and improving treatment outcomes. Curr Opin Pulm Med 7 (2001) 391-398
2. Young T., Peppard P.E., and Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165 (2002) 1217-1239
3. **The most important references are denoted by an asterisk. Morgenthaler T.I., Kapen S., Lee-Chiong T., et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 29 (2006) 1031-1035
4. Schmidt H.S., Clark R.W., and Hyman P.R. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 134 (1977) 183-185
5. Brownell L.G., West P., Sweatman P., Acres J.C., and Kryger M.H. Protriptyline in obstructive sleep apnea: a double-blind trial. N Engl J Med 307 (1982) 1037-1042
6. Smith P.L., Haponik E.F., Allen R.P., and Bleecker E.R. The effects of protriptyline in sleep-disordered breathing. Am Rev Respir Dis 127 (1983) 8-13
7. Whyte K.F., Gould G.A., Airlie M.A., Shapiro C.M., and Douglas N.J. Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep 11 (1988) 463-472
8. Series F., and Cormier Y. Effects of protriptyline on diurnal and nocturnal oxygenation in patients with chronic obstructive pulmonary disease. Ann Intern Med 113 (1990) 507-511
9. Series F., Marc I., Cormier Y., and La Forge J. Long-term effects of protriptyline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 147 (1993) 1487-1490
10. Schmidt H.S. l-tryptophan in the treatment of impaired respiration in sleep. Bull Eur Physiopathol Respir 19 (1983) 625-629
11. Sasse A., Conduit R., Ryan D., Woods W., and Tucker A.P. A pharmacotherapy for obstructive sleep apnea. Sleep 28 (2005) 1015-1016
12. *. Veasey S.C. Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. Am J Respir Med 2 (2003) 21-29
13. Sood S., Morrison J.L., Liu H., and Horner R.L. Role of endogenous serotonin in modulating genioglossus muscle activity in awake and sleeping rats. Am J Respir Crit Care Med 172 (2005) 1338-1347
14. Veasey S.C., Chachkes J., Fenik P., and Hendricks J.C. The effects of ondansetron on sleep-disordered breathing in the English bulldog. Sleep 24 (2001) 155-160
15. Stradling J., Smith D., Radulovacki M., and Carley D. Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial. J Sleep Res 12 (2003) 169-170
16. Carley D.W., Paviovic S., Janelidze M., and Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. Sleep 25 (2002) 391-398
17. Hanzel D.A., Proia N.G., and Hudgel D.W. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 100 (1991) 416-421
18. Kraiczi H., Hedner J., Dahlof P., Ejnell H., and Carlson J. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 22 (1999) 61-67
19. Sunderram J., Parisi R.A., and Strobel R.J. Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure. Am J Respir Crit Care Med 162 (2000) 925-929
20. Berry R.B., Yamaura E.M., Gill K., and Reist C. Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 22 (1999) 1087-1092
21. Aslan S., Isik E., and Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 25 (2002) 677-679
22. Berry R.B., Koch G.L., and Hayward L.F. Low-dose mirtazapine increases genioglossus activity in the anesthetized rat. Sleep 28 (2005) 78-84
23. Carley D.W., and Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 160 (1999) 1824-1829
24. Carley D., Olopade C., Seink S., and Radulovacki M. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 30 (2007) 35-41
25. Liu X., Sood S., Liu H., and Horner R.L. Opposing muscarinic and nicotinic modulation of hypoglossal motor output to genioglossus muscle in rats in vivo. J Physiol 565 (2005) 965-980
26. Gilman S., Chervin R.D., Koeppe R.A., Consens F.B., Little R., An H., et al. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. Neurology 61 (2003) 35-39
27. Hedner J., Kraiczi H., Peker Y., and Murphy P. Reduction of sleep-disordered breathing after physostigmine. Am J Respir Crit Care Med 168 (2003) 1246-1251
28. Hedner J., Kraiczi H., Peker Y., and Grote L. Reduction of sleep apnea after the orally available cholinesterase inhibitor donepezil. Sleep Med 6 (2005) S54-S55
29. Gothe B., Strohl K.P., Levin S., and Cherniack N.S. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest 87 (1985) 11-17
30. Davila D.G., Hurt R.D., Offord K.P., Harris C.D., and Shepard Jr. J.W. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 150 (1994) 469-474
31. Zevin S., Swed E., and Cahan C. Clinical effects of locally delivered nicotine in obstructive sleep apnea syndrome. Am J Ther 10 (2003) 170-175
32. Slamowitz D.I., Edwards J.K., Chajek-Shaul T., and White D.P. The influence of a transmucosal cholinergic agonist on pharyngeal muscle activity. Sleep 23 (2000) 543-550
33. Mulloy E., and McNicholas W.T. Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest 101 (1992) 753-757
34. Saletu B., Oberndorfer S., Anderer P., et al. Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality. Neuropsychobiology 39 (1999) 151-159
35. Hein H., Behnke G., Jorres R.A., and Magnussen H. The therapeutic effect of theophylline in mild obstructive sleep apnea/hypopnea syndrome: results of repeated measurements with portable recording devices at home. Eur J Med Res 5 (2000) 391-399
36. Orth M.M., Grootoonk S., Duchna H.W., de Zeeuw J., Walther J.W., Bauer T.T., et al. Short-term effects of oral theophylline in addition to CPAP in mild to moderate OSAS. Respir Med 99 (2005) 471-476
37. *. Javaheri S., Parker T.J., Wexler L., Liming J.D., Lindower P., and Roselle G.A. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 335 (1996) 562-567
38. Hu K., Li Q., Yang J., Hu S., and Chen X. The effect of theophylline on sleep-disordered breathing in patients with stable chronic congestive heart failure. Chin Med J (Engl) 116 (2003) 1711-1716
39. Andreas S., Reiter H., Luthje L., Delekat A., Grunewald R.W., Hasenfuss G., et al. Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure. Circulation 110 (2004) 2157-2162
40. Espinoza H., Antic R., Thornton A.T., and McEvoy R.D. The effects of aminophylline on sleep and sleep-disordered breathing in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 136 (1987) 80-84
41. Fischer R., Lang S.M., Leitl M., Thiere M., Steiner U., and Huber R.M. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 23 (2004) 47-52
42. White D.P., Zwillich C.W., Pickett C.K., Douglas N.J., Findley L.J., and Weil J.V. Central sleep apnea. Improvement with acetazolamide therapy. Arch Intern Med 142 (1982) 1816-1819
43. Tojima H., Kunitomo F., Kimura H., Tatsumi K., Kuriyama T., and Honda Y. Effects of acetazolamide in patients with the sleep apnoea syndrome. Thorax 43 (1988) 113-119
44. *. DeBacker W.A., Verbraecken J., Willemen M., Wittesaele W., DeCock W., and Van deHeyning P. Central apnea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med 151 (1995) 87-91
45. Verbraecken J., Willemen M., De Cock W., Coen E., Van de Heyning P., and De Backer W. Central sleep apnea after interrupting longterm acetazolamide therapy. Respir Physiol 112 (1998) 59-70
46. Nakayama H., Smith C.A., Rodman J.R., Skatrud J.B., and Dempsey J.A. Effect of ventilatory drive on carbon dioxide sensitivity below eupnea during sleep. Am J Respir Crit Care Med 165 (2002) 1251-1260
47. *. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 173 (2006) 234-237
48. Finnimore A.J., Roebuck M., Sajkov D., and McEvoy R.D. The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J 8 (1995) 230-234
49. Ohtake P.J., Simakajornboon N., Fehniger M.D., Xue Y.D., and Gozal D. N-methyl-d-aspartate receptor expression in the nucleus tractus solitarii and maturation of hypoxic ventilatory response in the rat. Am J Respir Crit Care Med 162 (2000) 1140-1147
50. Veasey S.C., Zhan G., Fenik P., and Pratico D. Long-term intermittent hypoxia: reduced excitatory hypoglossal nerve output. Am J Respir Crit Care Med 170 (2004) 665-672
51. Hedner J., Grunstein R., Eriksson B., and Ejnell H. A double-blind, randomized trial of sabeluzole-a putative glutamate antagonist-in obstructive sleep apnea. Sleep 19 (1996) 287-289
52. Radulovacki M., Pavlovic S., Rakic A., Janelidze M., Shermulis L., and Carley D.W. Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats. J Pharm Pharmacol 53 (2001) 1555-1559
53. Torvaldsson S., Grote L., Peker Y., Basun H., and Hedner J. A randomized placebo-controlled trial of an NMDA receptor antagonist in sleep-disordered breathing. J Sleep Res 14 (2005) 149-155
54. Guilleminault C., and Hayes B. Naloxone, theophylline, bromocriptine, and obstructive sleep apnea. Negative results. Bull Eur Physiopathol Respir 19 (1983) 632-634
55. Atkinson R.L., Suratt P.M., Wilhoit S.C., and Recant L. Naloxone improves sleep apnea in obese humans. Int J Obes 9 (1985) 233-239
56. Greenberg H.E., Rapoport D.M., Rothenberg S.A., Kanengiser L.A., Norman R.G., and Goldring R.M. Endogenous opiates modulate the postapnea ventilatory response in the obstructive sleep apnea syndrome. Am Rev Respir Dis 143 (1991) 1282-1287
57. Ferber C., Duclaux R., and Mouret J. Naltrexone improves blood gas patterns in obstructive sleep apnoea syndrome through its influence on sleep. J Sleep Res 2 (1993) 149-155
58. Schonhofer B., and Kohler D. Benzodiazepine receptor antagonist (flumazenil) does not affect sleep-related breathing disorders. Eur Respir J 9 (1996) 1816-1820
59. Popovic R.M., and White D.P. Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol 84 (1998) 1055-1062
60. Hensley M.J., Saunders N.A., and Strohl K.P. Medroxyprogesterone treatment of obstructive sleep apnea. Sleep 3 (1980) 441-446
61. Block A.J., Wynne J.W., Boysen P.G., Lindsey S., Martin C., and Cantor B. Menopause, medroxyprogesterone and breathing during sleep. Am J Med 70 (1981) 506-510
62. Pickett C.K., Regensteiner J.G., Woodard W.D., Hagerman D.D., Weil J.V., and Moore L.G. Progestin and estrogen reduce sleep-disordered breathing in postmenopausal women. J Appl Physiol 66 (1989) 1656-1661
63. Cistulli P.A., Barnes D.J., Grunstein R.R., and Sullivan C.E. Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax 49 (1994) 699-702
64. Keefe D.L., Watson R., and Naftolin F. Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. Menopause 6 (1999) 196-200
65. Manber R., Kuo T.F., Cataldo N., and Colrain I.M. The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. Sleep 26 (2003) 163-168
66. Wesstrom J., Ulfberg J., and Nilsson S. Sleep apnea and hormone replacement therapy: a pilot study and a literature review. Acta Obstet Gynecol Scand 84 (2005) 54-57
67. Saaresranta T., Polo-Kantola P., Rauhala E., and Polo O. Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep. Eur Respir J 18 (2001) 989-995
68. Rajagopal K.R., Abbrecht P.H., and Jabbari B. Effects of medroxyprogesterone acetate in obstructive sleep apnea. Chest 90 (1986) 815-821
69. Cook W.R., Benich J.J., and Wooten S.A. Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest 96 (1989) 262-266
70. Schneider B.K., Pickett C.K., Zwillich C.W., Weil J.V., McDermott M.T., Santen R.J., et al. Influence of testosterone on breathing during sleep. J Appl Physiol 61 (1986) 618-623
71. Liu P.Y., Yee B., Wishart S.M., Jimenez M., Jung D.G., Grunstein R.R., et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 88 (2003) 3605-3613
72. Stewart D.A., Grunstein R.R., Berthon-Jones M., Handelsman D.J., and Sullivan C.E. Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea. Am Rev Respir Dis 146 (1992) 1389-1393
73. Rajagopal K.R., Abbrecht P.H., Derderian S.S., Pickett C., Hofeldt F., Tellis C.J., et al. Obstructive sleep apnea in hypothyroidism. Ann Intern Med 101 (1984) 491-494
74. Grunstein R.R., and Sullivan C.E. Sleep apnea and hypothyroidism: mechanisms and management. Am J Med 85 (1988) 775-779
75. Lin C.C., Tsan K.W., and Chen P.J. The relationship between sleep apnea syndrome and hypothyroidism. Chest 102 (1992) 1663-1667
76. Skjodt N.M., Atkar R., and Easton P.A. Screening for hypothyroidism in sleep apnea. Am J Respir Crit Care Med 160 (1999) 732-735
77. Rosenow F., Reuter S., Deuss U., Szelies B., Hilgers R.D., Winkelmann W., et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol (Oxf) 45 (1996) 563-569
78. Mestron A., Webb S.M., Astorga R., Benito P., Catala M., Gaztambide S., et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151 (2004) 439-446
79. Grunstein R.R., Ho K.K., and Sullivan C.E. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121 (1994) 478-483
80. Ip M.S., Tan K.C., Peh W.C., and Lam K.S. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 55 (2001) 477-483
81. Herrmann B.L., Wessendorf T.E., Ajaj W., Kahlke S., Teschler H., and Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 151 (2004) 309-315
82. Smith P.L., Haponik E.F., and Bleecker E.R. The effects of oxygen in patients with sleep apnea. Am Rev Respir Dis 130 (1984) 958-963
83. Gold A.R., Bleecker E.R., and Smith P.L. A shift from central and mixed sleep apnea to obstructive sleep apnea resulting from low-flow oxygen. Am Rev Respir Dis 132 (1985) 220-223
84. Gold A.R., Schwartz A.R., Bleecker E.R., and Smith P.L. The effect of chronic nocturnal oxygen administration upon sleep apnea. Am Rev Respir Dis 134 (1986) 925-929
85. Landsberg R., Friedman M., and Ascher-Landsberg J. Treatment of hypoxemia in obstructive sleep apnea. Am J Rhinol 15 (2001) 311-313
86. Chauncey J.B., and Aldrich M.S. Preliminary findings in the treatment of obstructive sleep apnea with transtracheal oxygen. Sleep 13 (1990) 167-174
87. Farney R.J., Walker J.M., Elmer J.C., Viscomi V.A., and Ord R.J. Transtracheal oxygen, nasal CPAP and nasal oxygen in five patients with obstructive sleep apnea. Chest 101 (1992) 1228-1235
88. 2 on sleep-related disordered breathing in ambulatory patients with stable heart failure. Sleep 22 (1999) 1101-1106
89. Sakakibara M., Sakata Y., Usui K., Hayama Y., Kanda S., Wada N., et al. Effectiveness of short-term treatment with nocturnal oxygen therapy for central sleep apnea in patients with congestive heart failure. J Cardiol 46 (2005) 53-61
90. *. Shigemitsu M., Nishio K., Kusuyama T., Itoh S., Konno N., and Katagiri T. Nocturnal oxygen therapy prevents progress of congestive heart failure with central sleep apnea. Int J Cardiol 115 (2007) 354-360
91. Hudgel D.W., Hendricks C., and Dadley A. Alteration in obstructive apnea pattern induced by changes in oxygen- and carbon-dioxide-inspired concentrations. Am Rev Respir Dis 138 (1988) 16-19
92. 2 inhalation on central sleep apnea and arousals from sleep. Respiration 71 (2004) 493-498
93. *. Thomas R.J., Daly R.W., and Weiss J.W. Low-concentration carbon dioxide is an effective adjunct to positive airway pressure in the treatment of refractory mixed central and obstructive sleep-disordered breathing. Sleep 28 (2005) 69-77
94. Xiao G., Wang Z., Ke M., and Huang X. [The relationship between obstructive sleep apnea and gastroesophageal reflux and the effect of antireflux therapy]. Zhonghua Nei Ke Za Zhi 38 (1999) 33-36
95. Ing A.J., Ngu M.C., and Breslin A.B. Obstructive sleep apnea and gastroesophageal reflux. Am J Med 108 suppl 4a (2000) 120S-125S
96. Senior B.A., Khan M., Schwimmer C., Rosenthal L., and Benninger M. Gastroesophageal reflux and obstructive sleep apnea. Laryngoscope 111 (2001) 2144-2146
97. Steward D.L. Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing. Laryngoscope 114 (2004) 1525-1528
98. Resta O., Foschino-Barbaro M.P., Legari G., Talamo S., Bonfitto P., Palumbo A., et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 25 (2001) 669-675
99. Grunstein R., Wilcox I., Yang T.S., Gould Y., and Hedner J. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord 17 (1993) 533-540
100. Young T., Palta M., Dempsey J., Skatrud J., Weber S., and Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328 (1993) 1230-1235
101. Newman A.B., Nieto F.J., Guidry U., Lind B.K., Redline S., Pickering T.G., et al. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 154 (2001) 50-59
102. Peppard P.E., Young T., Palta M., Dempsey J., and Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. J Am Med Assoc 284 (2000) 3015-3021
103. *. Yee B.J., Phillips C.L., Banerjee D., Caterson I., Hedner J.A., and Grunstein R.R. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int J Obes (Lond) 31 (2007) 161-168
104. Schwartz A.R., Rowley J.A., O'Donnell C., King E.D., Mayor A., and Smith P.L. Effect of hypertension on upper airway function and sleep apnoea. J Sleep Res 4 (1995) 83-88
105. Carley D.W., Trbovic S.M., and Radulovacki M. Hydralazine reduces elevated sleep apnea index in spontaneously hypertensive (SHR) rats to equivalence with normotensive Wistar-Kyoto rats. Sleep 19 (1996) 363-366
106. Wilson C.R., Manchanda S., Crabtree D., Skatrud J.B., and Dempsey J.A. An induced blood pressure rise does not alter upper airway resistance in sleeping humans. J Appl Physiol 84 (1998) 269-276
107. Mayer J., Weichler U., Herres-Mayer B., Schneider H., Marx U., and Peter J.H. Influence of metoprolol and cilazapril on blood pressure and on sleep apnea activity. J Cardiovasc Pharmacol 16 (1990) 952-961
108. Planes C., Foucher A., Leroy M., Dartois N., Juste K., Baillart O., et al. Effect of celiprolol treatment in hypertensive patients with sleep apnea. Sleep 22 (1999) 507-513
109. Grote L., Wutkewicz K., Knaack L., Ploch T., Hedner J., and Peter J.H. Association between blood pressure reduction with antihypertensive treatment and sleep apnea activity. Am J Hypertens 13 (2000) 1280-1287
110. *. Kraiczi H., Hedner J., Peker Y., and Grote L. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. Am J Respir Crit Care Med 161 (2000) 1423-1428
111. Jokic R., Klimaszewski A., Mink J., and Fitzpatrick M.F. Surface tension forces in sleep apnea: the role of a soft tissue lubricant: a randomized double-blind, placebo-controlled trial. Am J Respir Crit Care Med 157 (1998) 1522-1525
112. Morrell M.J., Arabi Y., Zahn B.R., Meyer K.C., Skatrud J.B., and Badr M.S. Effect of surfactant on pharyngeal mechanics in sleeping humans: implications for sleep apnoea. Eur Respir J 20 (2002) 451-457
113. Kirkness J.P., Madronio M., Stavrinou R., Wheatley J.R., and Amis T.C. Relationship between surface tension of upper airway lining liquid and upper airway collapsibility during sleep in obstructive sleep apnea hypopnea syndrome. J Appl Physiol 95 (2003) 1761-1766
114. Canova C.R., Downs S.H., Knoblauch A., Andersson M., Tamm M., and Leuppi J.D. Increased prevalence of perennial allergic rhinitis in patients with obstructive sleep apnea. Respiration 71 (2004) 138-143
115. Kiely J.L., Nolan P., and McNicholas W.T. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 59 (2004) 50-55
116. Braver H.M., and Block A.J. Effect of nasal spray, positional therapy, and the combination thereof in the asymptomatic snorer. Sleep 17 (1994) 516-521
117. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Kales A., Tyson K., and Chrousos G.P. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 82 (1997) 1313-1316
118. Vgontzas A.N., Zoumakis E., Lin H.M., Bixler E.O., Trakada G., and Chrousos G.P. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 89 (2004) 4409-4413
119. Santamaria J., Iranzo A., Ma Montserrat J., and de Pablo J. Persistent sleepiness in CPAP treated obstructive sleep apnea patients: evaluation and treatment. Sleep Med Rev 11 (2007) 195-207
120. Kingshott R.N., Vennelle M., Coleman E.L., Engleman H.M., Mackay T.W., and Douglas N.J. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 163 (2001) 918-923
121. *. Pack A.I., Black J.E., Schwartz J.R., and Matheson J.K. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 164 (2001) 1675-1681
122. Dinges D.F., and Weaver T.E. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 4 (2003) 393-402
123. Schwartz J.R., Hirshkowitz M., Erman M.K., and Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 124 (2003) 2192-2199
124. Black J.E., and Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 28 (2005) 464-471
125. Arnulf I., Homeyer P., Garma L., Whitelaw W.A., and Derenne J.P. Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 64 (1997) 159-161
126. Heitmann J., Cassel W., Grote L., Bickel U., Hartlaub U., Penzel T., et al. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea?. Clin Pharmacol Ther 65 (1999) 328-335
127. Roth T., White D., Schmidt-Nowara W., Wesnes K.A., Niebler G., Arora S., et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 28 (2006) 689-706
128. Hirshkowitz M., Black J.E., Wesnes K., Niebler G., Arora S., and Roth T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 101 (2007) 616-627